更新于：2024-11-01

Extranodal NK-T-Cell Lymphoma

结外NK-T细胞淋巴瘤

更新于：2024-11-01

基本信息

别名

Angiocentric T-Cell Lymphoma、Angiocentric T-cell lymphoma、Angiocentric lymphoma

+ [55]

简介

An extranodal neoplasm, usually possessing an NK-cell phenotype and associated with EPSTEIN-BARR VIRUS. These lymphomas exhibit a broad morphologic spectrum, frequent necrosis, angioinvasion, and most commonly present in the midfacial region, but also in other extranodal sites.

关联

项与结外NK-T细胞淋巴瘤相关的药物

Linperlisib

林普利塞

靶点

PI3Kδ

作用机制

PI3Kδ抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2022-11-08

Sugemalimab

舒格利单抗

靶点

PDL1

作用机制

PDL1抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2021-12-20

Mitoxantrone liposomal(CSPC Pharmaceutical Group Ltd.)

盐酸米托蒽醌脂质体

靶点

Top II

作用机制

Top II抑制剂

在研机构

石药集团中奇制药技术（石家庄）有限公司 [+6]

原研机构

石药集团有限公司

在研适应症

外周T细胞淋巴瘤 [+25]

非在研适应症

晚期胃癌 [+11]

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2021-06-01

267

项与结外NK-T细胞淋巴瘤相关的临床试验

NCT05700448 / Not yet recruiting临床3期

A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)

The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.

开始日期2024-11-01

申办/合作机构

基石药业（苏州）有限公司

NCT06583083 / Recruiting临床2期IIT

A Multicenter, Phase 2, Randomized Trial of Sintilimab (PD-1 Antibody) With P-GEMOX Versus the P-GEMOX Regimen in the Teatment of Newly Diagnosed Advanced-stage Extranodal Natural Killer/T Cell Lymphoma (ENKTL) (SPIRIT-02)

Extranodal NK/T-cell lymphoma is a rare and highly aggressive subtype of non-Hodgkin lymphoma. While the overall survival rates have improved for early-stage ENKTL patients, the prognosis for those with advanced disease remains poor, and there is currently no standard treatment. PD-1/PD-L1 inhibitors have demonstrated significant efficacy in various cancers, and recent studies have shown promising results in extranodal NK/T-cell lymphoma as well. Although PD-1 antibodies have exhibited efficacy in relapsed or refractory patients, their effectiveness when combined with chemotherapy as a first-line treatment remains unclear. This study aims to evaluate the efficacy and safety of sintilimab combined with chemotherapy in a randomized controlled trial for newly diagnosed advanced extranodal NK/T-cell lymphoma patients, while also exploring potential biomarkers that may predict treatment outcomes, offering new therapeutic options for extranodal NK/T-cell lymphoma patients.

开始日期2024-10-22

申办/合作机构

中山大学

ChiCTR2400090798 / SuspendedN/AIIT

The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Lell Lymphoma: A Clinical Study

开始日期2024-10-15

申办/合作机构

四川大学华西医院（四川省国际医院）

100 项与结外NK-T细胞淋巴瘤相关的临床结果

登录后查看更多信息

100 项与结外NK-T细胞淋巴瘤相关的转化医学

登录后查看更多信息

0 项与结外NK-T细胞淋巴瘤相关的专利（医药）

登录后查看更多信息

3,508

项与结外NK-T细胞淋巴瘤相关的文献（医药）

2024-12-31·Hematology

Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma

Article

作者: Yan, Zhimin ; Wang, Hua ; Bai, Shenrui ; Fu, Bibo ; Zhu, Lewei ; Feng, Demei ; Liang, Yang ; Xia, Zhongjun ; Gale, Robert Peter

OBJECTIVEThe prognosis of extra-nodal NK/T cell lymphoma (ENKTL) is poor, and the optimal therapy remains controversial. This study aims to evaluate the safety and efficacy of a new combined modality therapy.METHODSPhase-2 study of pegaspargase, etoposide and gemcitabine (PEG) combined with involved field radiation therapy (IFRT) in newly-diagnosed patients with early-stage ENKTL. Patients received 4 course of PEG followed by IFRT. The primary endpoints were complete response (CR), partial response (PR), and objective response rate (ORR) after IFRT. Secondary endpoints included progression-free survival (PFS), overall survival (OS) and adverse events.RESULTS34 consecutive patients with Ann Arbor stage I/II were enrolled. 3 patients progressed on PEG, while the remaining 31 received IFRT. The ORR was 88.2% (30/34), included 28 (82.4%) complete and 2 (5.8%) partial responses. With a median follow-up of 56.0 months (Interquartile Range [IQR], 36.0-66.9 months), the estimated 5-year PFS and OS were 87.4% (95% Confidence Interval [CI],69.5%-94.8%) and 97.1% (95%CI, 80.1%-99.6%), respectively. Most adverse events were hematological and easily managed.CONCLUSIONSPEG followed by IFRT is a safe and effective initial therapy for early-stage ENKTL, demonstrating impressive PFS and OS rates. This promising approach warrants further validation in a randomized controlled trial (Registered at Clinicaltrials.gov NCT02705508).Trial registration: ClinicalTrials.gov identifier: NCT02705508.

2024-12-31·Human Vaccines & Immunotherapeutics

A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma

Article

作者: Chen, Xiaoyan ; Qin, Liping ; He, Yizi ; Li, Yajun ; Xiao, Ling ; Zeng, Ruolan ; Zhou, Hui

NK/T-cell lymphoma (NKTCL) is a rare type of non-Hodgkin lymphoma (NHL). Although L-asparaginase-based chemotherapy has significantly improved survival in early-stage patients, the prognosis is poor in advanced and relapsed or refractory patients. CD47 is a promising target for cancer immunotherapy. However, the expression of CD47 in NKTCL and the antitumor effect and mechanism of the anti-CD47 monoclonal antibody (mAb) AK117 in NKTCL remain unclear. Firstly, the expression level of CD47 protein in NKTCL cells was detected by immunoblot and flow cytometry. Secondly, in order to validate the role of CD47 downregulation in the proliferation, apoptosis, and cell cycle of NKTCL cells, we used shRNA transfection to knock down CD47 expression. We determined the effect of knocking down CD47 and the novel anti-CD47 antibody AK117 on the phagocytosis of NKYS and YTS cells by M2 macrophages in vitro. Finally, we assessed the ability of AK117 to inhibit tumor growth in an NKTCL xenograft model in which YTS cells were engrafted in SCID mice. The results showed that CD47 is relatively highly expressed in NKTCL cells. CD47 knockdown in NKTCL promoted phagocytosis by M2 macrophages in an in vitro coculture assay. The study also demonstrated that anti-CD47 mAb AK117 promoted phagocytosis of NKTCL cells by M2 macrophages. In addition, in vivo experiments showed that the anti-CD47 mAb AK117 significantly inhibited the growth of subcutaneous xenograft tumors in SCID mice compared to the control antibody IgG. Our results indicate that targeting CD47 monoclonal antibodies is a potential therapeutic strategy for NKTCL.

2024-12-01·Radiology Case Reports

Carotid space Burkitt lymphoma presenting with headache: A case report

Article

作者: Zadehmir, Mohadeseh ; Hoseinian, Mohamad ; Mashhadi, Amin ; Shahverdi, Afsaneh ; Masoodian, Sedigheh ; Mashhadi, Mahshid

Burkitt's lymphoma presents with diverse clinical manifestations, including rare extranodal occurrences. This report documents a unique case of primary Burkitt's lymphoma located in the carotid space, an infrequent presentation with significant diagnostic implications. A 25-year-old male presented with the sudden onset severe headache and nausea. Imaging revealed an infiltrative lesion encompassing the right carotid sheath, extending into the superior retropharynx and nasopharynx. Diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) mapping demonstrated significant restriction. A core needle biopsy confirmed Burkitt's lymphoma diagnosis. Following the initiation of chemotherapy, follow-up imaging showed significant tumor regression. This case highlights the diagnostic challenges associated with carotid space tumors and underscores the pivotal role of imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) in their comprehensive evaluation. Multidisciplinary management, including aggressive chemotherapy, is imperative for achieving favorable outcomes in rare extranodal lymphomas like Burkitt's. Further research is warranted to refine diagnostic and therapeutic approaches for managing such complex cases.

项与结外NK-T细胞淋巴瘤相关的新闻（医药）

2024-10-28

·基石药业官微

基石药业宣布British Journal of Clinical Pharmacology发表择捷美®群体药代动力学研究成果

2024年10月28日——基石药业（股票代码：2616.HK），一家专注于抗肿瘤药物研发的创新驱动型生物医药企业，今日宣布，公司自研的PD-L1抗体择捷美®（舒格利单抗注射液）群体药代动力学研究成果已在知名期刊《British Journal of Clinical Pharmacology》发表。基石药业首席执行官、研发总裁及执行董事杨建新博士表示： “该群体药代动力学研究分析不仅通过模型揭示了择捷美®在不同患者群体中的药代动力学特征，也为择捷美®标准剂量应用于不同患者群体的合理性提供了详实的科学证据。我们将继续致力于推动择捷美®的全球开发和上市进程，力争为更多患者提供创新的治疗选择。” 该研究通过群体药代动力学（PopPK）建模，整合了九项I-III期临床试验中1628名不同类型肿瘤患者的数据，涵盖了非小细胞肺癌、NK/T细胞淋巴瘤和食管鳞癌等多种适应症。研究结果显示，择捷美®的PopPK模型能充分描述其在人体内的药代动力学特征。虽然体重、白蛋白、性别、抗药抗体、肿瘤负荷和肿瘤类型对药物清除率有一定影响，但这些因素影响的幅度较小（均小于20%），在临床上无显著意义。模型分析进一步支持了择捷美®已获批的标准剂量（1200 mg、每三周一次给药）在不同患者群体中应用的合理性。结果表明，不同患者群体，包括老年患者、不同种族的患者以及肝肾功能轻中度受损的患者，在该剂量下均能实现充分的药物暴露，且无需针对特定协变量进行剂量调整，进一步表明了择捷美®用药的便利性、以及对改善患者依从性的潜在助益。此外，模型的建立也为临床上一些极端情况下（如：体重>115kg）的用药提供了指导。择捷美®是由基石药业研发的抗PD-L1单克隆抗体，择捷美®的开发是基于美国Ligand公司授权引进的OmniRat®转基因动物平台。该平台可一站式产生全人源抗体。作为一种全人源全长抗PD-L1单克隆抗体，择捷美®是一种最接近人体的天然G型免疫球蛋白4（IgG4）单抗药物，能降低在患者体内产生免疫原性及相关毒性的潜在风险，与同类药物相比择捷美®将具有独特优势。择捷美®独特分子设计使其具备双重作用机制，不仅阻断PD-1/PD-L1相互作用，还能通过介导PD-L1表达阳性的肿瘤细胞与肿瘤相关巨噬细胞（TAMs），在诱导抗体依赖性细胞吞噬（ADCP）的同时不损害效应性T细胞。这种差异化设计使择捷美®在不同类型的肿瘤中展现出了潜在同类最优的疗效和安全性。目前，中国国家药品监督管理局（NMPA）已批准择捷美®五项适应症：联合化疗一线治疗转移性鳞状和非鳞状NSCLC患者；治疗同步或序贯放化疗后未出现疾病进展的、不可切除、III期NSCLC患者；治疗复发或难治性结外NK/T细胞淋巴瘤患者；联合氟尿嘧啶类和铂类化疗药物一线治疗不可切除的局部晚期，复发或转移性食管鳞癌患者；联合含氟尿嘧啶类和铂类药物化疗用于表达PD-L1（综合阳性评分[CPS]≥5）的不可手术切除的局部晚期或转移性胃及胃食管结合部腺癌的一线治疗。欧盟委员会（EC）已批准舒格利单抗（商品名：Cejemly®）联合含铂化疗用于无EGFR敏感突变, 或无ALK, ROS1, RET基因组肿瘤变异的转移性NSCLC患者的一线治疗。此外，英国药品和医疗保健用品管理局（MHRA）已受理舒格利单抗联合含铂化疗用于无EGFR敏感突变, 或无ALK, ROS1, RET基因组肿瘤变异的转移性NSCLC患者的一线治疗的上市许可申请。目前，该申请正在审评过程中。基石药业（香港联交所代码: 2616）成立于2015年底，是一家专注于抗肿瘤药物研发的创新驱动型生物医药企业，致力于满足中国和全球癌症患者的殷切医疗需求。截至目前，公司已成功上市4款创新药、获批15项新药上市申请（NDA）以及9项适应症。当前研发管线均衡配置了潜在同类首创或同类最佳的抗体偶联药物（ADC）、多特异性抗体、以及免疫疗法和精准治疗药物在内的16款候选药物。同时，基石药业拥有一支资深管理团队，“全链条”覆盖临床前探索、临床转化、临床开发、药物生产、商务拓展、商业运营等关键环节。内容来源于网络，如有侵权，请联系删除。

免疫疗法抗体药物偶联物上市批准

2024-09-18

·今日头条

四款癌症疫苗杀入2024 ESMO大会，暴击五大癌种，近半数获完全缓解

欧洲肿瘤内科学会年会（ESMO）作为最具影响力的肿瘤学平台之一，旨在传播最新的前沿数据，了解肿瘤学的最佳实践和最新进展。在刚刚结束的2024 ESMO大会上，有三款癌症疫苗闪亮登场，其中也包括一款我国自研的癌症疫苗，“通过打一针唤醒免疫系统，杀伤癌细胞”的美好愿景将不再是天方夜谭，让我们一睹为快！一、四款癌症疫苗惊艳亮相2024 ESMO大会（一）IO102-IO103疫苗：第一款针对IDO和PD-L1免疫调节疫苗，近半数黑色素瘤患者完全缓解 2024 ESMO大会公布的数据显示，IO102-IO103癌症疫苗达到了针对晚期头颈部鳞状细胞癌（SCCHN）2期试验的主要终点，该疫苗与派姆单抗联用，客观缓解率（ORR）达到44.4%。 IO102-IO103疫苗实际上是两种疫苗的组合，每种疫苗都能激发并训练患者体内特定的T细胞，其中，IO102可诱导免疫细胞，攻击细胞内的IDO（酶吲哚胺-2,3-双加氧酶）；IO103可引导免疫细胞，攻击细胞膜内嵌入的PD-L1（蛋白质程序性死亡配体1），从而使免疫细胞能够识别并“记住”特定的癌细胞，最终杀死肿瘤微环境中的肿瘤细胞和免疫抑制细胞。它也是首创针对IDO和PD-L1免疫调节疫苗。 PD-1抑制剂是治疗转移性黑色素瘤（MM）的有效方法，然而超过50%的患者会因耐药，而出现病情进展。近期公布的3期IOB-013/KN-D18阶段性临床试验数据显示，IO102-IO103癌症疫苗联合帕博利珠单抗（中国首个获批上市的PD-1抑制剂），治疗晚期黑色素瘤的疗效良好，3期试验正在进行中。此前公布的1/2期临床试验（NCT03047928）结果也很惊艳，该研究共入组30例转移性黑色素瘤（MM）患者，入组接受IO102-IO103癌症疫苗+纳武单抗（nivolumab）治疗。结果显示：经研究者审核，客观缓解率（ORR）高达80% （CI，62.7%~90.5%），其中 43%的患者达到完全缓解，37%的患者达到部分缓解（PR）。中位无进展生存期（PFS）长达26个月（CI，15.4~69个月），详见下图。 ▲图源“Nat Med”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除下图展示了一位患者（患者MM42）在IO102-IO103癌症疫苗治疗前、治疗后（回输9次后）的PET-CT图像中靶病变的FDG代谢变化。 ▲图源“Nat Med”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除（二）我国自研WGc-043疫苗，治疗血液肿瘤和实体瘤的“全能选手”，疾病控制率近60% WGc-043是由我国WestGene生物制药公司研发的一款针对EBV阳性癌症的治疗性mRNA疫苗。EBV病毒感染人体后，可导致肺癌、宫颈癌、胃癌、肝癌、食道癌、鼻咽癌、乳腺癌等多种恶性肿瘤，这些都是WGc-043疫苗的潜在适应症，此外，该疫苗还可治疗血液肿瘤，目前处于T细胞淋巴瘤的I期。 WGc-043癌症疫苗是首个在中国和美国都获得新药IND批准的针对EBV相关肿瘤的mRNA治疗疫苗，具有里程碑似的重要意义！在2024年ESMO大会上，中国专家以口头会议形式，报告了WGc-043治疗NK/T细胞淋巴瘤（NKTCL）的Ⅰ期数据，这是一种罕见且具有侵袭性的血液肿瘤，通常与EBV感染有关。本次研究共入组7例标准治疗失败的EBV阳性复发或难治性NK/T细胞例淋巴瘤（NKTCL）患者，以肌肉注射方式给予WGc-043治疗后。结果显示：疾病控制率（DCR）高达57.14%，客观缓解率（ORR）达到42.86% ，其中， 3例患者达到部分缓解（PR），1例患者维持病情稳定（SD），详见下表。综上，WGc-043癌症疫苗在NKTCL患者中，表现出良好的有效性和安全性。 ▲数据源自“ESMO”，全球肿瘤医生网医学部整理汇总（三）ELI-002疫苗：暴击KRAS阳性胰腺癌/结直肠癌，完全缓解率高达24%！ ELI-002疫苗为一种针对KRAS阳性实体瘤的治疗性疫苗，由一种类似于“信号塔”的AMP-mKRAS-肽组成，可引导机体免疫系统，精准识别并及时摧毁携带KRAS突变的癌细胞，可用于治疗KRAS突变的胰腺导管腺癌（93%）、结直肠癌（50%）等。既往研究发现，在MRD（微小残留病灶）环境中，将肿瘤切除后，再注射ELI-002疫苗，可诱导功能性肿瘤定向KRAS突变特异性T细胞扩增，增加抗肿瘤活性的潜力，从而减少肿瘤生物标志物，并延迟复发。在本次ESMO大会上，再次提及了ELI-002疫苗，肯定了其在治疗难治性KRAS突变肿瘤中的疗效，可诱导高强度的T细胞反应，既可降低肿瘤标志物水平，还可降低复发及死亡风险，对84%的微小残留病（MRD）阳性复发患者均有免疫原性。在《自然医学》杂志上发表的最新文章中，报告了ELI-002疫苗的1期AMPLIFY-201临床研究（NCT05726864）结果。该研究共入组25例KRAS高复发风险的实体瘤患者（包括5例结直肠癌、20例胰腺癌），既往接受过手术、放化疗等治疗。入组接受ELI-002疫苗单一辅助治疗后，结果显示：从第1剂疫苗接种日期起，中位总生存期（OS）及中位无复发生存期（RFS）均为16.33个月（详见下图）。在治疗第6个月时，77%的患者出现了肿瘤标志物减少，其中 24%（6例）的患者获得了完全缓解（CR），这也意味着这6例患者的癌症奇迹般被清除了！ ▲图源“nature medicine”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除（四）mRNA-4359癌症疫苗暴击晚期肺癌、黑色素瘤等，半数患者达到病情稳定 mRNA-4359癌症疫苗是由Moderna（莫德纳）公司研发的一款针对晚期肺癌、黑色素瘤、其他实体瘤的mRNA疫苗。其工作原理是激活患者的免疫系统，在血液中产生能够识别两种目标蛋白质（PD-L1、IDO1）的免疫细胞，并动员免疫系统来摧毁它们。在2024年ESCO大会上，公布了mRNA-4359癌症疫苗的第一阶段试验结果，这也是该疗法的首次人体研究。本次入组的16例可评估疗效的晚期实体瘤患者，在接受mRNA-4359癌症疫苗单药治疗后。结果显示， 50%的患者达到病情稳定（SD），这也意味着这些患者原有肿瘤未继续增大，也未出现新的肿瘤，病情稳定最长持续41周。这项评估mRNA癌症免疫疗法的研究，有望为晚期癌症患者开发新的治疗方法迈出重要的第一步——英国首席研究员Debashis Sarker博士。二、小编寄语癌症疫苗经过数十年的发展，已从早期研究阶段，逐渐走向了临床，除了已获批上市的“古巴肺癌疫苗”外，还有200多款在研的癌症疫苗，矛头直指结直肠癌、胰腺癌、头颈癌、黑色素瘤、肺癌等多款癌种。近年来，我国也紧跟世界脚步，相继开展了多款癌症疫苗的临床研发，比如上文提到的成功杀入2024 ESMO大会的WGc-043疫苗，就是我国自研的一款同时针对血液肿瘤和实体瘤的“全能突破性癌症疫苗”！好消息是，目前我国有多款在研癌症疫苗，正在招募恶性肿瘤患者，包括但不限于肺癌、结直肠癌、肝癌、宫颈癌、食管癌、头颈癌等癌种！对此感兴趣的患者，可将近期病理报告、治疗经历等资料，提交至全球肿瘤医生网医学部，进行初步评估或了解详细的入排标准！三、参考资料 [1]Kjeldsen JW,et al.A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9. Erratum in: Nat Med. 2022 Apr;28(4):871. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904254/ [2]Pant S,et al.Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial[J].Nature medicine,2024:1-12. https://www.nature.com/articles/s41591-023-02760-3 [3]https://www.fiercebiotech.com/biotech/esmo-io-biotechs-vaccine-and-keytruda-combo-hit-primary-endpoint-phase-2-squamous-cell [4]https://www.onclive.com/view/phase-3-trial-of-first-line-io102-io103-pembrolizumab-to-continue-in-advanced-melanoma [5]https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/an-exploratory-study-to-assess-the-safety-immunogenicity-and-preliminary-anti-tumor-activity-of-the-ebv-mrna-vaccine-wgc-043-injection-in-patie [6]https://www.esmo.org/oncology-news/proof-of-concept-for-the-safety-and-immunogenicity-of-lymph-node-targeting-kras-mutation-specific-amphiphile-vaccine-and-promising-signal-of-clinical-activity [7]https://www.kcl.ac.uk/news/mrna-cancer-vaccine-potential-advanced-stage-cancer-patients-in-phase-1-trial [8]https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/first-in-human-phase-i-ii-monotherapy-dose-escalation-study-of-mrna-4359-an-mrna-encoded-pd-l1-ido1-antigen-specific-therapy-in-advanced-refra [9]https://www.kcl.ac.uk/news/mrna-cancer-vaccine-potential-advanced-stage-cancer-patients-in-phase-1-trial 本文为全球肿瘤医生网原创，未经授权严禁转载

疫苗临床3期临床2期临床结果信使RNA

2024-09-16

·PRNewswire

WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024

BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. Pioneering Advances in mRNA Therapeutics Continue Reading image_5030521_43293125 WGc-043, the world's first mRNA therapeutic vaccine targeting EBV-positive tumors to achieve IND approval in both China and the US, demonstrated exceptional safety, immunogenicity, and anti-tumor activity in the latest clinical trials. The vaccine is being developed specifically for adult patients with advanced EBV-positive solid tumours and refractory or relapsed EBV-positive lymphomas, diseases for which there are currently no effective, low-toxicity treatment options. Impressive Clinical Performance Recognized by ESMO Interim clinical data presented at ESMO 2024 highlighted the vaccine's ability to activate the patient's immune system, leading to the production of cytotoxic T cells, antigen-specific antibodies and memory T cells that target and destroy cancer cells. This novel mechanism offers a promising alternative to conventional CAR-T and monoclonal antibody therapies and also aims to prevent tumor recurrence, providing a triple benefit, particularly for patients with late-stage nasopharyngeal carcinoma and NK/T cell lymphoma. Innovative Technology and Global Impact WGc-043 is a testament to WestGene's proprietary mRNA platform, which includes cutting-edge innovations in mRNA sequence design, novel lipid nanoparticle (LNP) delivery systems, and scalable manufacturing processes. The vaccine was developed using WestGene's patented LNP technology, which is recognized for its superior efficacy and safety. This technology has been instrumental in overcoming the challenges associated with mRNA vaccine delivery and has positioned WestGene as a leader in the global mRNA therapeutic Expanding Horizons in Cancer Treatment The global market for mRNA cancer vaccines is expected to grow significantly, with estimates ranging from $230 billion to $300 billion by 2035. The success of WGc-043 at ESMO underscores the potential of mRNA technology not only to lead the field, but also to accelerate clinical development and provide safe, effective treatments for late-stage cancer patients. Looking Ahead WestGene Biopharma () remains committed to advancing its mRNA platform and expanding its pipeline to address unmet medical needs across a range of indications. The company's innovative approach and commitment to collaboration will continue to drive progress in the field of mRNA therapeutics and bring hope to patients worldwide. Photo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED